Here we report on the synthesis and biochemical characterization (enzymatic stability, cellular uptake, in vitro antitumor activity, membrane interaction and GnRH-receptor binding affinity) of novel short-chain fatty acid (SCFA) acylated daunorubicin-GnRH-III bioconjugates, which may serve as drug delivery systems for targeted cancer chemotherapy. Ser in position 4 of GnRH-III was replaced by Lys, followed by the acylation of its ε-amino group with various fatty acids. SCFAs are potentially chemoprotective agents by suppressing the growth of cancer cells and therefore may enhance the antitumor activity of the bioconjugates. We found that all synthesized bioconjugates had high cytostatic effect in vitro, were stable in cell culture medium for 6 h and degraded in the presence of rat liver lysosomal homogenate leading to the formation of an oxime bond-linked daunorubicin-Lys as the smallest active metabolite. In the presence of α-chymotrypsin, all compounds were digested, the degradation rate strongly depending on the type of fatty acid. The bioconjugate containing Lys(nBu) in position 4 was taken up most efficiently by the cancer cells and exerted higher in vitro cytostatic effect than the previously developed GnRH-III( 4 Lys(Ac), 8 Lys(Dau=Aoa)) or the parent GnRH-III(Dau=Aoa) bioconjugate. Our results could be explained by the increased binding affinity of the newly developed compound containing Lys(nBu) to the GnRH receptors.
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. It has been shown that a fiber and complex carbohydrate rich diet could be preventive for colon cancer [2] . Shortchain fatty acids (SCFAs) are produced by anaerob bacterial fermentation of dietary fiber and resistant starch within the large colon. Depending on the source, the major products are acetate, propionate, butyrate, valerate, hexanoate and branched SCFAs (isobutyrate and isovalerate). These SCFAs, especially butyrate, are known for their potential to act as chemopreventive agents by slowing cell growth and activating apoptosis in colon cancer cells [3] . It is currently accepted that the effects of butyrate are mainly caused by the regulation of the expression of specific genes through its histone deacetylase inhibitor activity [4] . It regulates proliferation of mucosal epithelial cells and it can also induce apoptosis in various human cancer cell lines (HT-29, HL-60, etc) by increasing the level of pro-apoptotic protein bak and/or decreasing the level of the anti-apoptotic protein p26-bcl-2 [2] . Butyrate may contribute to the detoxification of dietary carcinogens by inducing glutathione S-transferases (GSTs) in cancer cell lines. Although GST activity was induced only by butyrate, prevention of chemoresistance was caused by SCFA mixtures containing acetate, propionate, butyrate, valerate, hexanoate and the branched SCFAs (isobutyrate and isovalerate) [5] . Therefore, SCFAs may be an important component of drug delivery systems for targeted cancer chemotherapy.
Targeted chemotherapy is a modern oncological approach designed to increase the selectivity of cytotoxic drugs and consequently to prevent their toxic side effects. Considering that gonadotropin-releasing hormone (GnRH) receptors are highly expressed on various cancer cells, GnRH analogs can be used as targeting moieties for the attachment of anticancer drugs.
Apart from pituitary cells and reproductive organs, other organs express GnRH receptors only in a limited number or not at all, making them a selective target for cancer chemotherapy [6, 7] .
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Because of the unfavorable endocrine effect of the hormone molecules in targeted cancer therapy, in particular for the treatment of hormone independent tumors, research is focused on GnRH derivatives with decreased hormonal activity. The third isoform of GnRH (GnRH-III: Glp-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH 2 ), isolated from the sea lamprey (Petromyzon marinus), exerts negligible endocrine activity in mammals [8] , inhibits the proliferation of various cancer cells [9, 10] and binds to both type I and type II GnRH receptors [11] . To decrease the endocrine activity and increase the antitumor effect of GnRH-III, various analogs have been developed [9, 12] . It was found that not many changes in the sequence were allowed. In positions 5-7, single amino acid replacement was well tolerated for the endocrine, but not for the anticancer activity. Furthermore, the replacement of Ser by Lys or Lys(Ac) in position 4 did not have a major effect either on the endocrine activity or on the anticancer property of the peptides. In position 8, the elimination of the basic side chain function of lysine did not influence the anticancer activity, but it led to a decreased hormonal potency [9] . Therefore, in our previous studies, the side chain of 8 Lys was used to form symmetrical GnRH-III dimers and peptide-drug conjugates [10, 13] . Besides its anticancer activity and low hormonal effect, an ideal peptide based drug candidate should be stable in human serum and in the presence of digestive enzymes, especially if it is intended to be orally administered. Oral administration of drugs is considered to be the most convenient and economical route of treatment. It offers the advantage of self-administration with a high degree of patient acceptability and compliance [14] .
We have recently reported on the synthesis and biochemical characterization of a daunorubicin-GnRH-III bioconjugate in which 4 Ser was replaced by Lys(Ac). This
was evaluated on orthotopically developed C26 murine colon carcinoma bearing mice. The results showed that the bioconjugate had significantly higher antitumor activity than the parent bioconjugate [15] . Furthermore, the concentration dependent cellular uptake of GnRH-III( 4 Lys(Ac), 8 Lys(Dau=Aoa)) on MCF-7 cells was significantly higher compared to the nonacetylated version [15] . Taken together these previous findings and also considering the effect of SCFAs on tumor growth inhibition, it is assumed that SCFAs on the side chain of 4 Lys in GnRH-III( 4 Lys(X), 8 Lys(Dau=Aoa)) may increase not only the cellular uptake and enzymatic stability, but also the antitumor activity of the bioconjugates. Thus, in the present study we aimed at developing new derivatives containing SCFAs for targeted drug delivery.
Here we report on the synthesis and biochemical characterization (enzymatic stability, cellular uptake, in vitro antitumor activity, membrane interaction and GnRH-receptor binding affinity) of novel daunorubicin-GnRH-III bioconjugates in which Ser in position 4 was replaced by Lys, followed by the acylation of its ε-amino group with different saturated and unsaturated short-chain fatty acid chains of different length. The stability of the bioconjugates in cell culture medium was determined by high performance liquid chromatography. The degradation of the bioconjugates in the presence of rat liver lysosomal homogenate and their stability in the presence of the digestive enzyme α-chymotrypsin were investigated by liquid chromatography-mass spectrometry. Their in vitro cytostatic effect and the cellular uptake were evaluated on HT-29 human colon and MCF-7 human breast cancer cell lines.
Radioligand binding studies were performed on normal human pituitary sample (anterior lobe) and prostate cancer specimen.
Results and Discussion
Short-chain fatty acid acylated daunorubicin-GnRH-III derivative bioconjugates
One of the most promising approaches in modern oncology is the targeted cancer chemotherapy, which is based on the features of cancer cells that differ from the normal cells.
In this way, only the cancer cells are affected, resulting in fewer side effects. The essential advantage of this procedure is the improved selectivity and not necessarily the enhanced efficiency. It was found that receptors for various peptide hormones such as GnRH, somatostatin and bombesin are highly expressed on cancer cells; therefore, selectivity could be achieved by applying these peptide hormones as targeting moieties. One of the advantages of the GnRH analogs is that they exert an antitumor effect themselves. Therefore, GnRH derivatives as components of drug delivery systems may serve not only as targeting moieties, but also as antitumor agents. A promising GnRH containing bioconjugate, developed in A. V.
Schally's laboratory (AN-152) [16] , in which doxorubicin is attached to [D- 6 Lys]-GnRH-I, is currently in Phase-II clinical trial on ovarian and endometrial cancer [17, 18] .
We have previously reported on a daunorubicin-GnRH-III bioconjugate in which 4 Ser was replaced by Lys(Ac) and daunorubicin was attached to 8 Lys through an oxime bond [15] .
This compound, GnRH-III( 4 Lys(Ac), 8 Lys(Dau=Aoa)), had increased enzymatic stability, cellular uptake, in vitro cytostatic effect and in vivo tumor growth inhibitory activity, compared to the parent bioconjugate GnRH-III( 8 Lys(Dau=Aoa)).
The positive effect of the incorporation of 4 Lys(Ac) instead of 4 Ser as well as the apoptosis inducing activity of SCFAs [19] prompted us to develop new GnRH-III( 4 Lys(X),
All peptides were synthesized by solid phase methodology using Fmoc-chemistry.
Lys(ivDde) was incorporated in position 4 and Lys(Mtt) in position 8 as an orthogonal protecting scheme for lysine residues. The cleavage of the ivDde protecting group and the acylation of 4 Lys with different short-chain fatty acids were carried out prior to the removal of Mtt under mild acidic conditions, followed by the attachment of Boc-Aoa-OH. All compounds were cleaved from the resin with TFA in the presence of appropriate scavengers.
Daunorubicin was conjugated to the aminooxyacetylated GnRH-III( 4 Lys(X)) derivatives by oxime ligation, which was carried out under slightly acidic conditions (pH 5.0). The structures of the synthesized compounds are schematically represented in Fig. 1 .
All bioconjugates were purified by semipreparative RP-HPLC and the purified compounds were characterized by analytical RP-HPLC and mass spectrometry (Table 1 and Supplementary material Fig.s S1 -S7 ). As previously reported [21, 22] , the fragmentation of the glycosidic bond during the ESI-mass spectrometric analysis could be observed, resulting in the loss of daunosamine (-129, -147). These fragments were assigned in all mass spectra by an asterisk.
Enzymatic stability/degradation of bioconjugates
Determination of the stability or the metabolic properties of a new drug candidate is one of the most important steps during the drug discovery and development process. In vitro approaches, such as stability/degradation studies in the presence of gastrointestinal or lysosomal enzymes, can be used for the early estimation and prediction of the in vivo stability and metabolism [23] . The aim of the targeted cancer chemotherapy is to specifically deliver the chemotherapeutic agents to the cancer cells, in order to prevent the side effects. Therefore, the linkage between the anticancer drug and the targeting moiety in the bioconjugates must have high stability in circulation or gastrointestinal tract, to avoid the toxic side effects caused
by an early drug release before reaching the site of action. Nevertheless, the intracellular drug release from the bioconjugates is required for their antitumor activity [24] . In the case of the reported bioconjugates, an oxime bond was formed between the C13 keto group of daunorubicin and the aminooxyacetyl group of the GnRH-III derivatives. The oxime bond is chemically stable between pH 3 and 8 [25] , as well as under in vitro and in vivo biological experimental conditions [26] . Moreover, the daunorubicin-GnRH-III bioconjugates must possess increased stability in the presence of digestive enzymes present in stomach and intestine in order to be suitable for oral administration. In our previous work, we reported that the bioconjugate GnRH-III( 4 Lys(Ac), 8 Lys(Dau=Aoa)) was stable in human serum and in the presence of pepsin and trypsin even after 24 h of incubation [15, 22] . In the presence of α-chymotrypsin, the -3 Trp-4 Lys(Ac)-peptide bond was cleaved in the bioconjugate; however, the degradation rate was slower than in the case of -3 Trp- 4 Ser-in the parent bioconjugate. In the present study, the stability/degradation of the bioconjugates was evaluated in the presence of rat liver lysosomal homogenate, in cell culture medium and in the presence of α-chymotrypsin.
The stability of GnRH-III( 4 Lys(X), 8 Lys(Dau=Aoa)) bioconjugates in cell culture medium was monitored by analytical RP-HPLC. All bioconjugates were stable at 37°C for 6 h (under the same conditions and time period used for the treatment of cells in vitro), since only the intact bioconjugates could be detected in the HPLC chromatograms (supplementary material, Fig. S8 ).
In the presence of α-chymotrypsin, similarly to our previous results, the - Comparing the results obtained in the present study (e.g., GnRH-III( 4 Lys(nBu), 8 Lys(Dau=Aoa)) -64% intact bioconjugate after 6 h) with the previous ones (e.g., GnRH-III( 4 Lys(Ac), 8 Lys(Dau=Aoa)) -33% intact bioconjugate after 6 hours) [22] , one can conclude that the acylation of 4 Lys with short-chain fatty acids led to increased stability of the bioconjugates in the presence of the digestive enzyme chymotrypsin; therefore, GnRH-III( 4 Lys(X), 8 Lys(Dau=Aoa) might be good candidates for oral administration. In contrast, the iBu containing bioconjugate proved to be the most susceptible one (only 10% of intact compound was detected in the reaction mixture after 6 h).
The degradation of the bioconjugates in the presence of rat liver lysosomal homogenate was also investigated by LC-MS. As shown in Fig. 1 and Table S2 , all seven bioconjugates were digested in the presence of lysosomal enzymes resulting in various peptide fragments; however, in case of the bioconjugate containing myristic acid, a very low amount of detectable metabolites was generated due to its low solubility. In agreement with
our previous results, no free daunorubicin was detected by LC-MS. In all cases, the smallest drug containing fragment was H-Lys(Dau=Aoa)-OH (detected in the mass spectra at m/z 729.5 (1+)). We have previously shown that this fragment was able to bind to DNA [22] . The mass spectra recorded after 2 and 24 h of incubation of the bioconjugates 1 -7 with the lysosomal homogenate are shown in the Supplementary material, Table S1 and Fig.s S11 -S17.
Interestingly, a fragment was detected by mass spectrometry at m/z 581.2 (1+), which might be assigned to <EHWK-OH peptide, indicating the cleavage of the amide bond between the side chain of 4 Lys and the fatty acids [10, 27] . However, the unambiguous identification of this fragment and of the free SCFA release requires further investigations.
Secondary structure determination by circular dichroism spectroscopy
To investigate the effects of the 4 Lys-acylation with different short-chain fatty acids on the secondary structure of the bioconjugates, circular dichroism (CD) spectra were recorded in water and in trifluoroethanol. All CD spectra of aqueous solutions of bioconjugates were characterized by a strong negative band around 200 nm and a positive band at 230 nm, with a shoulder at 250 nm, indicating a predominantly unordered conformation. A negative band around 290 nm, most probably caused by interactions between aromatic residues (Trp and daunorubicin), was also present in all spectra [28] . The CD spectra recorded in trifluoroethanol were characterized by an intensive negative band around 200 nm with a shoulder at around 210 nm, a positive band at 230 nm and another one at 250 nm, also indicating a predominantly unordered structure. A negative band around 290 nm, most probably caused by interactions between aromatic residues (Trp and daunorubicin), was also present in all spectra. The spectra of bioconjugates 1-7 were compared to the spectra of the
The data indicated that the secondary structure of the bioconjugates was not influenced by the type of the fatty acids (supplementary material, Fig.s S18 and S19). 94.5%) concentration, respectively [15] . It has to be mentioned that [D-Lys 6 (Dau=Aoa)]-GnRH-I showed similar cellular uptake as the GnRH-III bioconjugates containing the butyrate isomers ( Fig.s 2C and 2D ). These data suggest that not only the length of the SCFAs has an influence on the cellular uptake.
Cellular uptake of the bioconjugates on MCF-
Cytostatic effect of the bioconjugates
The in vitro cytostatic effect of the bioconjugates was determined on MCF-7 human breast and HT-29 human colon cancer cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The IC 50 values were determined from the doseresponse curves ( Table 2 ). The replacement of 4 Ser by the short-chain fatty acid acylated 4 Lys led to an increased cytostatic effect compared to the parent compound and the GnRH-III( 4 Lys(Ac), 8 Lys(Dau=Aoa)) on both tested human cancer cell lines, whereas myristoylation of 4 Lys resulted in a decreased cytostatic effect. This result might be explained by its low solubility in cell culture medium. The majority of the bioconjugates had higher cytostatic effect on MCF-7 than on HT-29 cells, which is in agreement with our previously reported data [22] showing that daunorubicin containing GnRH-III bioconjugates had lower antitumor activity on HT-29 human colon cancer cell line [12] . In case of GnRH-III( 4 Lys(iBu), 8 Lys(Dau=Aoa)) and GnRH-III( 4 Lys(nBu), 8 Lys(Dau=Aoa)), the IC 50 values on HT-29 and MCF-7 cells were comparable, probably due to the fact that the n-butyrate and isobutyrate can induce apoptosis and inhibit the proliferation of HT-29 cells [19] . On MCF-7 cells, the cytostatic effect of the bioconjugates containing n-butyrate or isobutyrate was slightly, but not significantly higher than of other compounds, although the cellular uptake was much higher Considering all these data, we can conclude that the replacement of 4 Ser by shortchain fatty acid acylated Lys in the GnRH-III sequence led to an increased cytostatic effect of daunorubicin-GnRH-III bioconjugates, in particular in case of butyrate and isobutyrate containing bioconjugates. The cellular uptake and the in vitro cytostatic effect of the newly developed bioconjugates were significantly increased compared to the compounds previously synthesized and characterized in our laboratory. We were further interested in the interaction between the bioconjugates and the cell membrane, as well as in the binding affinity of the bioconjugates to the GnRH receptors.
Characterization of the lipophilicity of the GnRH-III( 4 Lys(X), 8 Lys(Dau=Aoa)) bioconjugates
To reach the targeted cancer cells, drugs have to be transported through several membranes. Therefore, the hydrophobicity of the compound, which affects its absorption, bioavailability, metabolism or its interaction with lipid membranes, is in the focus of rational drug design. In the present work, using the classical shake-flask method and HPLC detection [29] , the octanol-water partition coefficient and logP of the compounds were determined.
LogP was calculated using the following equation: [30] . The membrane affinity of the bioconjugates or their compatibility with the lipid molecules is determined from the obtained quantitative information about the influence of the bioconjugates on the stability, structure and permeability of the lipid film.
In the penetration experiments, the lipid monolayer was compressed in the Langmuir balance to reach a surface pressure of 15 or 25 mN/m and the barrier was stopped. These surface pressures were chosen considering the compactness of the cell membrane close to these values [31] . A solution of the bioconjugates was injected into the subphase and the change of surface pressure was recorded for an hour. The results are shown in Table 3 .
All bioconjugates penetrated either the less or the more dense monolayer, exhibiting affinity to the lipid. As expected, the degree of penetration into the denser lipid layer (25 mN/m) was smaller than the penetration into the less dense monolayer (15 mN/m).
The bioconjugates containing no fatty acid or having a chain of 1, 2, 3, 4 or 5 carbon atoms penetrated the monolayer at a quite similar rate ( 
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From the penetration experiments, we can conclude that all bioconjugates showed affinity to the lipid monolayer; increasing the chain length of the fatty acid in the bioconjugates enhanced the penetration ability significantly only in case of the bioconjugate with myristic acid. Therefore, we may conclude that the cellular uptake takes place on a receptor-mediated way and might be influenced by the receptor binding affinity.
Binding of daunorubicin-GnRH derivative bioconjugates to GnRH receptors
In order to determine the potency of (Table 2) .
Taken together, these results suggest that not only the binding of the compounds to the GnRH receptors has an influence on their efficacy, but also the proper drug release (metabolite formation), which might not be very efficient in case of oxime bond-linked daunorubicin attached to D-Lys.
Comparing the investigated bioconjugates containing GnRH-III derivatives as targeting moieties, it can be concluded that the GnRH-III( 4 Lys(nBu), 8 Lys(Dau=Aoa)) has the highest affinity to the GnRH receptors both on human pituitary and human prostate cancer.
Conclusions
In the present work, GnRH-III modified with SCFAs in position 4 was employed as a targeting moiety to which daunorubicin was attached via an oxime bond leading to the formation of drug delivery systems for targeted cancer chemotherapy.
All investigated bioconjugates were stable at least for 6 h in cell culture medium. The stability of the compounds was also evaluated in the presence of the digestive enzyme of the intestinal tract, α−chymotrypsin. According to the LC-MS analyses of the digestion mixtures, all bioconjugates were digested and the degradation rate strongly depended on the type of fatty acid. Moreover, the stability of all bioconjugates except the bioconjugate 2, was enhanced compared to the most efficient compound GnRH-III( 4 Lys(Ac,), 8 Lys(Dau=Aoa)) previously developed in our laboratories.
The degradation of the bioconjugates in the presence of rat liver lysosomal homogenate was also investigated. In all cases, the smallest drug containing fragment M A N U S C R I P T 
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Experimental Section
Chemicals
All amino acid derivatives and Rink-Amide MBHA resin were purchased from Iris Biotech GmBH (Marktredwitz, Germany). Boc-aminooxyacetic acid (Boc-Aoa-OH), (Budapest, Hungary).
All reagents and solvents were of analytical grade or highest available purity. After completion of the synthesis of the protected decapeptides, the ivDde-protecting group of the ε-NH 2 group of 4 Lys was removed by 4% hydrazine in DMF (12 x 5 min); afterwards, the acylation of the ε-NH 2 group with short-chain fatty acids of different chain length was achieved using 3 eq fatty acid (propionic, n-butyric, isobutyric, isovaleric, caproic)
Synthesis of oxime bond-linked GnRH-III( 4 Lys(X), 8 Lys(Dau=Aoa)) bioconjugates
anhydride or crotonic acid chloride: DIPEA (1:1, mol/mol) for 2 h. In case of myristic acid, the carbonic acid was coupled using DIC, HOBt coupling reagents (3eq each to the resin capacity). After removing the Mtt-protecting group from the ε-NH 2 group ofM A N U S C R I P T
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2% TIS (triisopropylsilane) in DCM for 6 × 5 min), Boc-Aoa-OH was coupled for 2 h using DIC, HOBt coupling reagents (3 eq each to the amino group).
Aminooxyacetylated peptides were cleaved from the resin using a mixture of 95% TFA, 2.5% TIS and 2.5% water (v/v/v) in the presence of 10 eq free aminooxyacetic acid as "carbonyl capture" reagent for 1.5 h at room temperature and then precipitated with ice-cold diethyl ether, washed three times with diethyl ether and solubilized in 10% acetic acid prior to lyophilization [32] . The crude products were purified by semipreparative RP-HPLC, analyzed by mass spectrometry and immediately used in the next synthetic step after evaporation of the solvent. The conjugation of daunorubicin to the aminooxyacetylated GnRH-III( 4 Lys(X),
The aminooxyacetylated peptide was cleaved from the resin as described above (see 
RP-HPLC
The crude peptides and the bioconjugates were purified on a KNAUER 2501 HPLC system (H. Knauer, Bad Homburg, Germany) using a semipreparative Phenomenex Luna C18 column (250 mm x 10 mm) with 10 µm silica (100 Å pore size) (Torrance, CA, USA). Linear Peaks were detected at 220 nm.
Mass spectrometry
Electrospray (ESI)-mass spectrometric analyses were carried out on an Esquire 3000+ ion trap mass spectrometer (Bruker Daltonics, Bremen, Germany). Spectra were acquired in M A N U S C R I P T
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22 the 50 -2500 m/z range. Samples were dissolved in a mixture of 50% methanol, 48% water and 2% acetic acid.
Liquid chromatography-mass spectrometry (LC-MS) was carried out on an Esquire 3000+ ion trap mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped with an Agilent 1100 HPLC system and a diode array detector (Agilent, Waldbronn, Germany).
Peptides were separated on a Vydac MS C18 column (150mm x 1 mm; 300 Å, 3 µm) (Hesperia, CA) using a linear gradient from 90% solvent A (0.1% formic acid in water (v/v)) and 10% solvent B (0.1% formic acid in acetonitrile (v/v)) to 70% solvent B over 60 minutes at a flow rate of 50 µL/min. Spectra were recorded in positive ion mode in the 100 -2500 m/z range.
Stability of GnRH-III( 4 Lys(X), 8 Lys(Dau=Aoa)) bioconjugates in cell culture medium
Bioconjugates 1 -7 were dissolved in water (20% of the final volume) and then the solutions were diluted with serum free DMEM cell culture medium (final bioconjugate concentration: 0.5 mg/mL). The mixtures were incubated at 37°C for 6 h and samples of 50 µL were taken every hour. The stability of the samples was monitored using analytical RP-HPLC under the conditions described above.
Degradation of GnRH-III( 4 Lys(X), 8 Lys(Dau=Aoa)) bioconjugates in rat liver lysosomal homogenate
The rat liver lysosomal homogenate was prepared as previously described [22] . The 
In vitro cytostatic effect of GnRH-III( 4 Lys(X), 8 Lys(Dau=Aoa)) bioconjugates
In vitro cytostatic effect of the bioconjugates was determined by 3-(4, where OD treated and OD control correspond to the optical densities of treated and control cells, respectively. Cytostasis% was plotted as a function of concentration, fitted to a sigmoidal curve and the 50% inhibitory concentration (IC 50 ) value was determined from these curves.
Each experiment was repeated three times and the average IC 50 values are presented in Table   2 .
Circular dichroism spectroscopy
Circular dichroism (CD) spectra were recorded on a Jasco J-715 spectropolarimeter at Normal pituitary sample (anterior lobe) was collected at autopsy and human prostate cancer specimen was obtained from a patient at the time of initial surgical treatment. The local Institutional Ethics Committee approved the collection and use of these specimens for these studies. Preparation of membranes for receptor binding studies was performed as previously described [35] . Briefly, the samples were thawed and cleaned, and then ]GnRH-I was prepared by the chloramines-T method and purified by RP-HPLC in our laboratory [35] . GnRH-I receptor assays were carried out as reported [35] using in vitro ligand competition assays based on binding of 
Data Analysis
Specific ligand-binding capacities and affinities were calculated by the Ligand-PC computerized curve-fitting program of Munson and Rodbard [36] . Structures of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.
In vitro cytostatic effect of the bioconjugates.
Colon and breast cancer cell lines. 
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